Redwood AI Announces $3.5 Million Special Warrant Private Placement to Advance AI-Powered Chemistry Solutions

Private Placement Details and Warrant Features

Redwood AI structured its private placement as a special warrant offering, providing flexibility to institutional investors. The company is issuing 1,663,000 special warrants priced at $2.11 each, raising approximately $3.5 million in gross proceeds. Each special warrant converts into one unit without further consideration or action from the holder.

Each unit consists of one common share and one common share purchase warrant. The warrants allow holders to acquire additional common shares at $2.48 per share for 60 months following the closing date. This dual warrant structure offers investors leveraged exposure to Redwood AI’s stock performance over five years while potentially diluting existing shareholders.

Investor and Placement Agent Information

The private placement involves a single U.S. institutional investor, reflecting a concentrated investor base for this capital raise. The investor’s identity remains undisclosed. Maxim Group LLC serves as the exclusive placement agent, managing negotiations and deal structuring between Redwood AI and the investor.

The single-investor structure may indicate strategic alignment or capital raise size constraints. Institutional investors typically perform rigorous due diligence before investing, signaling confidence in Redwood AI’s AI-driven chemistry platform and market position.

Automatic Exercise Provisions and Prospectus Qualification

The offering includes an automatic exercise feature whereby each special warrant converts into one unit on the "Qualification Date," defined as the earlier of four months plus one day after closing or the date a prospectus supplement is filed. This mechanism eliminates exercise risk and facilitates seamless equity ownership transfer.

If the prospectus supplement is not filed within 90 days post-closing, each special warrant will convert into 1.10 units instead of one, incentivizing Redwood AI to expedite prospectus qualification and compensating investors for regulatory delays beyond 90 days.

Regulatory Approvals and Prospectus Filing Status

The closing of the offering is subject to Canadian Securities Exchange approval, a critical condition for completion. Redwood AI has filed a preliminary short form base shelf prospectus with Canadian provincial regulators, setting the regulatory foundation for the financing. Upon receipt of the final base prospectus, the company plans to file a prospectus supplement to qualify the distribution of units issuable upon warrant exercise.

This regulatory process ensures investor protection through full disclosure and is standard for Canadian capital market financings of this magnitude. Redwood AI commits to commercially reasonable efforts to file the prospectus supplement promptly after final prospectus receipt. The timing of these filings impacts the automatic exercise date and the potential 1.10 unit conversion adjustment.

Allocation of Proceeds and Capital Deployment

Net proceeds from the placement will be allocated to working capital and general corporate purposes. The company has not detailed specific allocations across R&D, sales and marketing, operations, or other areas. This approach allows Redwood AI to flexibly deploy capital based on evolving priorities and market conditions.

As an AI-driven software and analytics provider focused on accelerating chemistry research, working capital typically supports platform development, talent retention, customer acquisition, and infrastructure scaling. This $3.5 million raise aligns with Redwood AI’s strategic positioning in AI-assisted drug discovery, development, and defense and safety applications.

Resale Restrictions and Compliance with U.S. Securities Laws

Securities issued under this private placement will be subject to Canadian and U.S. resale restrictions, limiting short-term liquidity. Such restrictions prevent immediate resale by institutional investors, protecting public shareholders from potential share price pressure.

The securities are not registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the U.S. or to U.S. persons without registration or applicable exemptions. Despite this, Redwood AI is accepting investment from a U.S. institutional investor, indicating reliance on exemptions such as Regulation S or other safe harbors under U.S. securities law.

Company Overview and AI-Driven Chemistry Focus

Redwood AI provides AI-based software and analytics solutions for chemical and pharmaceutical development. The company integrates chemistry, AI, and manufacturing expertise to streamline drug synthesis and scale-up. Its platform aims to accelerate and optimize the development of new therapies and chemistry applications.

Positioned within the computational drug discovery sector, Redwood AI leverages machine learning combined with chemical synthesis and pharmaceutical development expertise to reduce time and costs in early-stage drug discovery. The company also targets defense and safety applications, indicating broader platform utility beyond pharmaceuticals.

Trading Listings and Market Accessibility

Redwood AI is listed on three exchanges: the Canadian Securities Exchange (CSE: AIRX), the OTCQB Venture Market in the U.S. (OTCQB: RDWCF), and the Frankfurt Exchange in Germany (Ticker: Y0N, WKN: A422EZ). Multi-exchange listings provide investors with trading flexibility across regions, though liquidity varies by venue.

The CSE listing reflects Redwood AI’s Canadian venture-stage technology status. The OTCQB listing facilitates access for U.S. investors, while the Frankfurt listing opens European market participation. The recent private placement from a U.S. institutional investor underscores ongoing investor interest across Redwood AI’s trading platforms.

Forward-Looking Statements and Associated Risks

The announcement includes standard forward-looking statements highlighting risks that may impact the offering’s timing and completion. These include potential delays or failure to obtain regulatory approvals such as CSE approval, and uncertainties regarding prospectus receipt and supplement filing.

Additional risks involve market condition changes and operational or financial challenges. These disclosures emphasize the contingent nature of the transaction and inherent uncertainties in regulatory and prospectus qualification processes.

Investor Guidance and Upcoming Milestones

The offering is expected to close on July 20, 2026, pending CSE approval. Investors should follow CSE announcements and Redwood AI filings for closing confirmation and updates on prospectus qualification.

Key regulatory milestones include final base prospectus receipt and prospectus supplement filing, which determine the automatic exercise date and potential increase to 1.10 units per warrant. The 90-day prospectus filing deadline falls on July 19, 2026, from the expected closing date. Failure to meet this deadline triggers the enhanced warrant conversion ratio, offering investor protection but increasing dilution risk for current shareholders. Stakeholders should monitor updates on prospectus progress and regulatory developments closely.